67th Annual Scientific Sessions of the American College of Cardiology 2018
Prof Greg Schwartz Rationale and design of ODYSSEY Outcomes
read more »Posted on 11 March 2018 |
Posted in Videos,
67th Annual Scientific Sessions of the American College of Cardiology 2018
ODYSSEY Outcomes: alirocumab reduces cardiovascular events and death after acute coronary syndrome
Top-line results presented at the 67th Scientific Sessions of the American College of Cardiology, Orlando, Florida provide definitive evidence for targeting PCSK9 inhibition to patients at highest risk with persistently elevated LDL cholesterol levels despite intensive statin therapy. Although further data are needed, this is…
read more »Posted on 10 March 2018 |
Posted in 67th Annual Scientific Sessions of the American College of Cardiology 2018
ODYSSEY OUTCOMES to report at ACC.2018
The second completed cardiovascular outcomes study with a PCSK9 inhibitor will be up first at the first latebreaker session at the American College of Cardiology Scientific Sessions this March. ODYSSEY OUTCOMES with alirocumab follows reporting of FOURIER with evolocumab and the terminated SPIRE studies with…
read more »Posted on 1 February 2018 |
Posted in News,
67th Annual Scientific Sessions of the American College of Cardiology 2018
